



Press Release

ChromaCon AG acquires assets and intellectual property of Separicon GmbH

Zurich, January 2016

Separicon GmbH was founded in 2011 to market continuous chromatography processes and equipment related to non-Life Science industries, being complementary to ChromaCon's IP for processes addressing customers in the Life Science industry. As ChromaCon and its scale-up partner LEWA Process Technologies (Devens, MA, USA) extend their collaboration in marketing intellectual property related to continuous processes, the IP acquired from Separicon will extend the customer base for continuous processes in industrial biotechnology, nutraceuticals, natural active substances, omega fatty acids, rare earth metal extraction and water remediation.

Michael Bavand, CEO of ChromaCon commented: "The complementary IP from Separicon will allow us to significantly extend our customer basis and that of our scale-up partner LEWA Process technologies. As large-scale chromatography is best operated continuously, our portfolio processes will help to create economic process solutions in areas where process chromatography so far has been too expensive."

About ChromaCon AG

ChromaCon AG is a private Life Science Tool company located in Zürich, Switzerland, providing best-in-class process solutions to the biopharmaceutical industry. ChromaCon has developed and patented novel process principles, process control, equipment designs and operating software for batch, cyclic and continuous chromatography, providing significant CAPEX and OPEX cost savings and enabling scalable chromatographic solutions for large scale purification applications. The Contichrom® laboratory-scale equipment is co-marketed worldwide by ChromaCon and its partners. ChromaCon has provided global licenses for its process technologies to LEWA Process Technologies (Devens, MA, USA) for implementation into scale-up systems. ChromaCon also develops and markets affinity purification solutions for column and membrane chromatography applications and tools for site-specific protein conjugation.

ChromaCon Contact

To find out more about ChromaCon please contact us directly or visit our website.

Dr. Michael Bavand, CEO, info@chromacon.com, www.chromacon.com